
Kanada
Tradegate
| Börsenplatz | Tradegate |
| Letzter Kurs | 0,0355 EUR |
| Performance | 0,00 % |
| Kurszeit | 10.07.26 |
| Vortageskurs | 0,0355 EUR |
| 52-Wochen Hoch | 0,0915 EUR |
| 52-Wochen Tief | 0,0325 EUR |
| 2022 | 2023 | 2024e | |
|---|---|---|---|
| KGV | -2,52 | -2,19 | -3,53 |
| Gewinn je Aktie | -0,07 | -0,03 | -0,03 |
| 2023 | 2024 | 2025 | ||
|---|---|---|---|---|
| Umsatz | 0 | 0 | 0 | |
| EBITDA | -2 | 0 | 0 | |
| EBIT | -2 | 0 | -6 | |
| Gewinn | -3 | -3 | -5 |
Das denkt die wallstreetONLINE Community über Hemostemix. Was ist Ihre Meinung? Diskutieren Sie gerne gleich mit!
danke Victor für die Info.
und wenn man denkt, es geht nicht mehr ...
und alles Gute für das "Neue Jahr"
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
TMX Newsfile
Wed, December 31, 2025 at 8:38 PM GMT+1 6 min read
https://finance.yahoo.com/quote/HMTXF/
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceeds of CDN$480,000, through the issuance of 4,000,000 common shares of the Company at a price of $0.12 per common share.
The proceeds from the private placement will be used for general working capital purposes, including advancing the Company's regulatory, clinical, and commercialization initiatives related to ACP-01 (VesCell), Hemostemix's autologous angiogenic cell therapy platform.
All securities issued pursuant to the private placement are subject to a statutory hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange ("TSXV"). The private placement remains subject to final acceptance by the TSXV.
hm, je besser die Nachrichten und Fortschritte, desto mehr wird der Kurs gedrückt.
08:37 Uhr · 4investors · Darwin |
08:00 Uhr · wO Chartvergleich · Carl Zeiss Meditec |
06:25 Uhr · Small- & MicroCap Investment · Nurexone BiologicAnzeige |
06:21 Uhr · Sharedeals · Moderna |
06:05 Uhr · Small- & MicroCap Investment · Bristol-Myers SquibbAnzeige |
| Name | Hemostemix Inc |
| Kurzname | Hemostemix |
| Namenszusatz | Registered Shs |
| Kategorie | Aktien |
| Aktientyp | Stammaktien |
| WKN | A2QQGU |
| ISIN | CA4236943060 |
| Symbol | 2VF0 |
| Branche | Biotechnologie |
| Land | |
| Referenzwährung | CAD |
| Aktienanzahl | 205,00 Mio. |
| Marktkapitalisierung | 7,38 Mio. EUR |
| Geschäftsjahresende | Dezember |
| Name | Hemostemix Inc |
| Stadt | Calgary, AB |
| Land | |
| Webseite | www.hemostemix.com |